Fortis Clinical Research Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 21-04-2024
- Paid Up Capital ₹ 4.90 Cr
as on 21-04-2024
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2017
- Revenue -99.16%
(FY 2017)
- Profit -118.70%
(FY 2017)
- Ebitda -216.16%
(FY 2017)
- Net Worth -91.22%
(FY 2017)
- Total Assets -70.98%
(FY 2017)
About Fortis Clinical Research
- CIN/LLPIN
U73100DL2005PLC134482
- Company No.
134482
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
29 Mar 2005
- Date of AGM
25 Sep 2017
- Date of Balance Sheet
31 Mar 2017
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Fortis Clinical Research Limited offer?
Fortis Clinical Research Limited offers a wide range of products and services, including Graduation & High Education Programs, Medical Educational Service, Bioequivalence Study.
Who are the key members and board of directors at Fortis Clinical Research?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivinder Singh  | Director | 25-Jul-2005 | Current |
| Malvinder Singh | Director | 25-Jul-2005 | Current |
| Harpal Singh | Director | 18-Jul-2005 | Current |
Financial Performance and Corporate Structure Insights of Fortis Clinical Research.
Fortis Clinical Research Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 99.16% decrease. The company also saw a substantial fall in profitability, with a 118.7% decrease in profit. The company's net worth observed a substantial decline by a decrease of 91.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fortis Clinical Research?
In 2017, Fortis Clinical Research had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Oscar Investments LimitedActive 46 years 10 monthsShivinder Singh and Malvinder Singh are mutual person
- Rhc Holding Private LimitedActive 17 years 8 months
Shivinder Singh and Malvinder Singh are mutual person
- Finserve Shared Services Private LimitedActive 13 years 2 months
Shivinder Singh and Malvinder Singh are mutual person
- Shimal Healthcare Private LimitedActive 16 years 8 months
Shivinder Singh and Malvinder Singh are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Fortis Clinical Research?
Fortis Clinical Research has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fortis Clinical Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fortis Clinical Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
